ESEvren Saban

Evren Saban

*This is an algorithmically generated author record based on publicly available information.

Evren Saban has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of Disinfection of Phi6 Virus Bacteriophage on Fomites by Various Methods and a Prototype for IR Application

    by Baki Karaböce, Rauf Hamid, Evren Saban, Hüseyin Sözeri, Erkan Danacı, Ahsen Aydın Böyük, Hüseyin Okan Durmuş, Lev Dorosinskiy, Oğuzhan Kızılbey, Semanur Bilecik, et al.


  • Comparative evaluation of peptide vs. protein-based calibration for quantification of cardiac troponin I using ID-LC-MS/MS

    by Meltem Asicioglu, Claudia Swart, Evren Saban, Emrah Yurek, Nevin Gul Karaguler, Merve Oztug

    Objectives: An analytical protocol based on isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS), which includes a peptide-based calibration strategy, was developed and validated for the determination of cardiac troponin I (cTnI) levels in clinical samples. Additionally, the developed method was compared with a protein-based calibration strategy, using cTnI serving as a model for low-abundant proteins. The aim is to evaluate new approaches for protein quantification in complex matrices, supporting the metrology community in implementing new methods and developing fit-for-purpose SI- traceable peptide or protein primary calibrators. Methods: To establish traceability to SI units, peptide impurity correction amino acid analysis (PICAA) was conducted to determine the absolute content of signature peptides in the primary standards. Immunoaffinity enrichment was used to capture cTnI from human serum, with a comparison between microbeads and nanobeads to improve enrichment efficiency. Parallel reaction monitoring was used to monitor two signature peptides specific to cTnI. Various digestion parameters were optimized to achieve complete digestion. Results: The analytical method demonstrated selectivity and specificity, allowing the quantification of cTnI within 0.9–22.0 μg/L. The intermediate precision RSD was below 28.9 %, and the repeatability RSD was below 5.8 % at all concentration levels, with recovery rates ranging from 87 % to 121 %. The comparison of calibration strategies showed similar LOQ values, but the peptide-based calibration exhibited significant quantitative bias in recovery rates. The data are available via ProteomeXchange (PXD055104). Conclusions: This isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method, based on peptide calibration, successfully quantified cTnI in human serum. Comparing this with protein-based calibration highlighted both the strengths and potential limitations of peptide-based strategies.


  • Open Access

    LUNGBANK: A Novel Biorepository Strategy Tailored for Comprehensive Multi-Omics Analysis and P-Medicine Applications in Lung Cancer

    by Di̇lEk Demi̇rCan Çeker, Volkan Baysungur, Serdar Evman, İlKer Kolbaş, Abdurrahi̇m Gördebi̇l, Si̇nEm M. Nalbantoğlu, Yusuf Tambağ, Ömer Kaçar, Ahmet Mi̇dİ, Hati̇cE Aslanoğlu, et al.

    Background/aim: LUNGBANK was established as a pioneering biorepository dedicated to lung cancer. Designed for streamlined biospecimens handling, it employs high-volume technologies to secure high-quality samples. Fortified with robust data management, LUNGBANK efficiently integrates diverse datasets. This strategic infrastructure positions LUNGBANK as more than a biospecimens repository; it operates as a sophisticated platform for advanced lung cancer research, amplifying the potential for meaningful discoveries.Materials and methods: LUNGBANK is intricately designed to streamline the collection, transfer, storage, and processing of biospecimens, employing high-volume technologies to ensure the acquisition of high-quality biological specimens. The system is fortified with robust data management protocols, facilitating efficient integration of diverse datasets. This strategic infrastructure ensures that LUNGBANK not only serves as a repository of biospecimens but also operates as a sophisticated platform for advanced lung cancer research.Results: LUNGBANK plays an essential role in furnishing a rich collection of biospecimens essential for unraveling the molecules and mechanisms linked to lung cancer. Rigorous standard operating procedures guided the meticulous collection of biospecimens, subjecting them to stringent quality control measures before inclusion in the study. Moreover, LUNGBANK has proven valuable in the establishment of patient-derived systems. The incorporation of cutting-edge technologies guarantees the acquisition of top-tier data, thereby amplifying the likelihood of substantial breakthroughs in both contemporary translational research and traditional histological evaluations.Conclusion: The establishment of LUNGBANK marks a significant stride towards addressing the pressing need for effective diagnostic and therapeutic systems in lung cancer research. By facilitating the collection and analysis of high-quality biospecimens, LUNGBANK serves as a valuable resource for unraveling the molecular intricacies of lung cancer initiation and progression. This comprehensive system not only supports Project LUNGMARK but also contributes to the broader landscape of personalized medicine, tailoring interventions to the specific needs of lung cancer patients.


  • Development of UME CRM 1008: certified reference material for C-reactive protein

    by Merve Oztug, Evren Saban, Meltem Asicioglu, Alper Isleyen, Muslum Akgoz


  • Inactivation of viruses on surfaces by infrared techniques

    by Baki Karaböce, Evren Saban, Ahsen Aydın Böyük, Hüseyin Okan Durmuş, Rauf Hamid, Ahmet Baş